News

OWise breast cancer app proven to be effective tool in cancer treatment process

Innovative patient support app shown in peer-reviewed medical journal to improve patient-doctor interactions and is recommended by 90% of patients and clinicians

London, 23 June 2016 – OWise breast cancer, the first mobile app to offer patients personalised medical support throughout their treatment, was the subject of a validation study now published in the Journal of Medical Internet Research – Cancer. The investigation by the University Medical Centre Utrecht, which is the first validation study of a mobile breast cancer app to be published in a peer-reviewed medical journal, strongly supports the use of OWise breast cancer as a shared-decision making tool that is highly valued by both clinicians and patients.

In addition to offering breast cancer patients personalised medical information, OWise also offers tracking tools that enable patients to record their treatment experiences, side effects and overall quality of life, alongside a range of other helpful features. OWise makes personalised treatment easier and more effective, allowing changes in levels of pain, sickness and fatigue to be easily captured and shared with healthcare professionals, who can then use the data that patients record in the app to inform decisions on treatment options.

The scientific article in the Journal of Medical Internet Research Cancer [JMIR Cancer 2016, Jun 07, 2(1): e8] describes that users of OWise report an increased feeling of control over their lives whilst undergoing treatment and that healthcare professionals note that the patient-doctor dialogue has improved.

“A breast cancer diagnosis can quickly turn a person’s life upside down. We’re very proud to help clinicians and patients make the best treatment decisions possible, and to ease a challenging time in every patient’s life,” said Dr. Anne Bruinvels, the app’s inventor and CEO. “We’re thrilled that the results in the Journal of Medical Internet Research – Cancer validate what we’ve been hearing from patients and clinicians since we launched in 2013, and we hope to be able to provide this free tool to as many breast cancer patients as possible.”

The original app was developed in the Netherlands in collaboration with patients to provide the most valuable support possible from the diagnosis. Based on its success, Dr. Bruinvels was awarded a Fellowship by the NHS Innovation Accelerator, a programme geared toward making new ideas and technologies more readily available to patients, to support the roll-out of OWise breast cancer across the NHS.

The OWise breast cancer app can be downloaded from www.owise.uk and from the iTunes and Play app stores.

About OWise
www.owise.uk

OWise is the first mobile app and website to offer breast cancer patients personalised medical information throughout their treatment.

Designed by Dr. Anne Bruinvels, OWise was developed by medical scientists to support patients and their physicians during the treatment process. By using the mobile app or website, patients can record in real time the experiences they have as they undergo treatment, including side effects and overall quality of life. Through the application, patients can also receive information about their condition and wellbeing as well as helpful tips on topics to discuss with their doctor. A cancer diagnosis can leave patients feeling out of control of their own body. OWise puts power back in their hands, allowing patients to track their individual progress and understand how they react to their medications. The app not only empowers patients; it also provides clinicians with an understanding of how their patients are reacting to various treatments, thus creating a platform for effective, personalised treatment.

Watch a video tutorial of OWise breast cancer: http://vimeo.com/67466501
Read the OWise validation study in JMIR Cancer: http://cancer.jmir.org/2016/1/e8/

About the NHS Innovation Accelerator (NIA)
https://www.england.nhs.uk/ourwork/innovation/nia/

The NIA is one of a range of programmes designed to support innovation development within the NHS. The programme is positioned at the later stages of innovation – working to speed up the process of spreading and embedding great ideas that have already demonstrated their value in the healthcare system.

 

OWise: the innovative breast cancer app offering a helping hand to patients throughout their treatment 

London, 9 February 2016 OWise breast cancer, the first mobile app to offer patients personalised medical support throughout their treatment, is launched in the UK today.

OWise is the first healthcare app to provide personalised medical information and tracking tools to support breast cancer patients with information throughout their treatment. The app enables patients to record their treatment experiences, side effects and overall quality of life as well as offering a range of other helpful features. For example, changes in the level of pain, sickness and fatigue can be easily captured and shared using OWise.

Clinicians can use the data which patients recorded in the app to inform decision-making about treatment options, supporting a personalised treatment approach. Originally launched in the Netherlands in 2013, users of OWise have reported an increased feeling of control over their life whilst undergoing treatment; healthcare professionals noted that the patient-doctor dialogue improved.

Following this success, the app’s inventor, Dr. Anne Bruinvels, was awarded a Fellowship by the NHS Innovation Accelerator to support the roll‑out of the breast cancer app across the NHS. OWise breast cancer has been developed in collaboration with patients to provide the most valuable support possible from the moment of diagnosis. It is supported by the NHS Innovation Accelerator, which aims to make new ideas and technologies more readily available to patients.

Jolijn, an OWise user who has advanced breast cancer, said: “When I received the diagnosis of breast cancer my world was turned upside down. In addition to treatment plans, examinations and results there was so much anguish and sadness. OWise creates order in this chaos and keeps it that way. It is truly a fantastic support!”

Dr. Samantha Barrell, Chief Executive of Taunton and Somerset NHS Foundation Trust, said: “This mobile app really supports patients positively through the physical and emotional challenges of having breast cancer. It is also a tremendous tool for supporting the relationship between a patient and their clinician during their treatment as well as for breast cancer services as a whole.”

To mark the launch of OWise breast cancer in the UK, the app is introduced to breast cancer specialists at the Pan-London Clinical Breast Cancer Forum, organised by the London Cancer Alliance. OWise breast cancer can be downloaded from www.owise.uk and from the iTunes and Play app stores.

For more information about OWise please visit www.owise.uk or contact Dr. Anne Bruinvels at anneb@pxhealthcare.com 

Notes to editors:

About OWise
OWise has been developed by medical scientists to support patients and their physicians during the treatment process; it aims to ‘empower the patient’. By using the mobile app or website, patients can receive personalised treatment information and tailor-made question suggestions to prepare for conversations with their doctors. Patients can register how they feel at different stages of their treatment, this can help physicians understand how a patient is responding to certain medications. Different symptoms, such as patients’ fatigue, nausea and pain can be tracked and viewed in graph-format which enables easy sharing with their treating physician or nurse. This allows patients to get a better insight into the effects of medicines on their well-being, while clinicians can obtain detailed information about the condition of their patients in between hospital visits. This enables doctors to adjust the treatment if and when necessary.

The development of OWise breast cancer was initiated by medical researcher and NHS Innovation Accelerator Fellow Dr. Anne Bruinvels. The initiative is based on her desire to improve the outcomes of breast cancer treatment, while supporting patients during their medical treatment. In addition to the support that OWise provides to patients and doctors, the fully anonymised and aggregated user data is used for medical research to improve the outcome of treatments for breast cancer in general. This way, global digital health applications like OWise can make an important impact on healthcare worldwide. 

Watch a video tutorial of OWise breast cancer:   http://vimeo.com/67466501 

About the NHS Innovation Accelerator (NIA)
The NIA is one of a range of programmes designed to support innovation development within the NHS. The programme is positioned at the later stages of innovation – working to speed up the process of spreading and embedding great ideas that have already demonstrated their value in the healthcare system. For more information, please visit https://www.england.nhs.uk/ourwork/innovation/nia/  

 

CE-mark for OWise breast cancer, the mobile app that supports patients 

OWise: one of the few medical apps to comply with European standards for safety

Amsterdam, 7 May 2014 – OWise breast cancer, the iPhone en Androïd app, which supports patients and provides doctors and scientists with insights into the effect of treatments, has been CE-marked. A CE mark designates that medical devices, including medical apps, comply with the European regulatory standards for safety and usage. 

The manufacturers of OWise, who have previously fitted it with a range of strict privacy and security measures, demonstrate herewith that they are serious about making software that is safe and trustworthy to use while caring about the privacy of its users. “It is for us of prime importance that patients are well supported throughout their treatment, which is why we wanted to make sure that OWise is safe to use and fit for purpose, says Dr. Anne Bruinvels, initiator of OWise. “Therefore, we are very pleased with the CE mark for OWise breast cancer. It demonstrates that we, as developers of medical apps, will do everything in our power to offer supportive, safe and reliable medical apps to cancer patients.”

OWise breast cancer offers patients and physicians insight into the course of the breast cancer treatment
OWise has been developed by medical scientists to support patients and their treating physicians during the treatment process. Using the ‘patient-engagement’ mobile app or website (www.owise.eu / www.owise.nl) patients receive a personalised treatment report, written in easily understandable language and based on the national guidelines for the treatment of breast cancer. Also they can simply register how they feel and how they react to medication. Subsequently, how, for example, patients’ fatigue, nausea and pain vary of time can be viewed in graph-format and easily be shared with their treating physician or nurse. This enables patients to get a better insight into the effects of drugs on their well being while treating clinicians can obtain detailed information about the condition of their patients in between hospital visits. This enables doctors to adjust the treatment if and when necessary.

Supporting medical research
The development of OWise breast cancer was initiated by medical researcher Dr. Anne Bruinvels. The initiative was based on her desire to improve research into breast cancer while supporting patients during their medical treatment. In addition to the support that OWise™ provides to patients and doctors, the fully anonymised and aggregated user data is applied to scientific research into improved and more effective treatments for breast cancer. This way, global, digital health applications like OWise™ can make an important impact on health care worldwide. 

Further developments of OWise
Recently, OWise breast cancer was awarded the prize for the most promising health app of 2013 at the Health App Awards in the Netherlands and the company was voted most innovative European digital health company (J&J Digital Health Challenge 2013). OWise breast cancer is the first product of Px HealthCare. The company is planning to expand the application of OWise to prostate, lung and colon cancer, in addition to developing an exercise-app for women with breast cancer. As an international venture, Px HealthCare aims to roll out its products globally, improving the treatment and health outcome of cancer patients worldwide.  

Video of Dutch OWise launch:  http://www.youtube.com/watch?v=5iMP98CsvLw&yt:cc=on
(Please make sure that you switch on the Captions in the YouTube browser by clicking on the screen and selecting Captions On).

Video tutorial of OWise breast cancer:  http://vimeo.com/67466501 

Note to editors:
For more information about OWise please see www.owise.eu or www.owise.nl. Or contact Dr. Anne Bruinvels at anneb@pxhealthcare.com. 

 

Px HealthCare, Creators of Novel Health Technology Helping Cancer Patients, Win Top Innovation Prize 

Dutch makers of OWise breast cancer selected as most innovative European digital health company  

London, 21 November 2013 – Px HealthCare B.V., an Amsterdam-based company established by medical scientists that develops mobile apps for cancer patients providing them with personalised medical support, has taken first place in the inaugural Digital Health Masterclass Challenge hosted by Janssen Healthcare Innovation and Johnson & Johnson Innovation in London.

OWise, the digital technology supporting cancer patients, exemplifies how European healthcare is being transformed
During the finals of the Digital Health Challenge, Px HealthCare presented the concept and results of OWise breast cancer, a Dutch smartphone app and website that not only supports patients, but also provides doctors and scientists insights into the effect of treatments. Pitching to a select panel of judges against 19 fellow digital health start-ups at the Masterclass Challenge, Px Healthcare secured first place and the top prize of €30,000 to help grow their offering.

The cutting-edge OWise technology, designed to personalise medical support for patients with cancer and improve the patient-doctor relationship, was viewed as an important digital health innovation that is already making an impact on today’s health ecosystem in Europe.

The event showcased the diversity of innovative digital health solutions on the horizon in Europe to help tackle some of the most pressing health challenges facing patients, their families and healthcare professionals.

Further developments of OWise
OWise breast cancer
is the first product of Px HealthCare, a socially-motivated enterprise founded in 2012. Earlier this year OWise™ breast cancer was awarded with the prize for the most promising health app of 2013 at the Health App Awards in the Netherlands. The company, which is continuously improving its OWise™ technology, is currently evaluating the impact the app has on breast cancer patients and doctors, in collaboration with the University Medical Centre Utrecht.

In addition to developing an exercise-app for women with breast cancer, Px HealthCare is looking to expand the application of OWise™ to colon, prostate and lung cancer. As an international venture, Px HealthCare aims to roll out its products globally, conducting research to improve the treatment and outcome of cancer worldwide.

Video of the J&J Digital Health Masterclass finals: http://masterclass.jnjinnovation.com/ (Please scroll down the page to watch the video)

Video of OWise™ launch:  http://www.youtube.com/watch?v=5iMP98CsvLw&yt:cc=on (Please make sure that you switch on the Captions in the YouTube browser by clicking on the screen and selecting Captions On).

Video tutorial of OWise™ breast cancer:  http://vimeo.com/67466501

Note to editors
For more information about OWise please see www.owise.eu or www.owise.nl. Or contact Dr. Anne Bruinvels at anneb@pxhealthcare.com.

For the press release of Janssen Healthcare Innovation, please see http://www.businesswire.com/news/home/20131121005789/en/Digital-Health-Technology-Cancer-Patients-Wins-Top    

 

OWise breast cancer is a - certified app
Copyright © 2017
Px HealthCare Ltd.
London Bioscience Innnovation Centre
2 Royal College Street
London NW1 ONH
United Kingdom
This website uses cookies. Find out more.